Olmesartan Medoxomilo Sandoz Farmacêutica

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo Sandoz Farmacêutica, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Olmesartan Medoxomilo Sandoz Farmacêutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Medoxomilo Sandoz Farmacêutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil is used to manage high blood pressure by targeting the renin‑angiotensin system. - Hypertension: Lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure: Used as part of combination therapy to improve cardiac output and symptoms. - Diabetic nephropathy: Helps slow progression of kidney damage associated with diabetes. - Post‑myocardial infarction: Assists in blood‑pressure control to lower the chance of recurrent events.

Olmesartan medoxil may cause a range of adverse reactions.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea

Serious or Rare Side Effects: - Angio‑edema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation

When prescribing Olmesartan medoxil, clinicians should consider several safety aspects. - Renal function: Assess baseline kidney function and monitor periodically. - Electrolytes: Check serum potassium levels, especially if combined with potassium‑sparing diuretics. - Pregnancy: Contra‑indicated ; avoid use in pregnancy for the development of fetal toxicity. - Elderly patients: Initiate at lower dose and monitor for orthostatic hypotension. - Drug interactions: Review  "). - Store at ");

t 

The     """"  \